At the 2011 ESACT meeting, 15-18 May in Vienna, Austria, Novozymes Biopharma will present two scientific posters showing study findings on industrial, stem and therapeutic cell culture.
The posters highlight the application of animal-free recombinant supplements in cell-based viral vaccine production as well as animal-free cryopreservation and recovery media.
Customers can get more information or request a copy of the scientific posters at booth 117 at the 2011 ESACT meeting, or alternatively, through the company website.
The first new poster, entitled Application of animal-free recombinant bioactive protein supplements to improve the performance of cell-based viral vaccine production, demonstrates the potential of protein supplements to improve growth performance of cell culture media in the absence of serum for cell types important in viral vaccine production.
The second poster, entitled Animal-free cryopreservation and recovery media, examines recombinant human albumin (rAlbumin) for its ability to replace serum in the cryopreservation of CHO and hybridoma (Sp2/0) cells.
Recombinant forms of other protein components of serum are also assessed for their ability to support cell growth during the initial recovery period following thawing.
The findings of both studies will be presented at ESACT 2011.
During the meeting, Dr Nicholas Timmins, research fellow at the Australian Institute of Bioengineering and Nanotechnology, University of Queensland, will deliver a presentation entitled Ultra-high-yield manufacture of red blood cells (RBC) in fully defined animal component free medium.
The presentation will demonstrate how using Novozymes' recombinant transferring and albumin products can eliminate the use of animal- and donor-derived medium components in RBC production.
The presentation will take place on 16 May during Session II: cells as therapies and stem cells.
